JP2025513745A - 新規抗ｆｇｆｒ２抗体 - Google Patents

新規抗ｆｇｆｒ２抗体 Download PDF

Info

Publication number
JP2025513745A
JP2025513745A JP2024557632A JP2024557632A JP2025513745A JP 2025513745 A JP2025513745 A JP 2025513745A JP 2024557632 A JP2024557632 A JP 2024557632A JP 2024557632 A JP2024557632 A JP 2024557632A JP 2025513745 A JP2025513745 A JP 2025513745A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557632A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023185778A5 (https=
JP2025513745A5 (https=
Inventor
ティエンティエン チョウ
チンリン トゥー
シューホア ハン
フェイ ポン
シュエヤン ヤン
Original Assignee
ハンチョウ チョンメイホアトン ファーマシューティカル カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンチョウ チョンメイホアトン ファーマシューティカル カンパニー，リミティド filed Critical ハンチョウ チョンメイホアトン ファーマシューティカル カンパニー，リミティド
Publication of JP2025513745A publication Critical patent/JP2025513745A/ja
Publication of JPWO2023185778A5 publication Critical patent/JPWO2023185778A5/ja
Publication of JP2025513745A5 publication Critical patent/JP2025513745A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024557632A 2022-03-28 2023-03-28 新規抗ｆｇｆｒ２抗体 Pending JP2025513745A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/083269 2022-03-28
CN2022083269 2022-03-28
PCT/CN2023/084213 WO2023185778A1 (en) 2022-03-28 2023-03-28 Novel anti-fgfr2 antibodies

Publications (3)

Publication Number Publication Date
JP2025513745A true JP2025513745A (ja) 2025-04-30
JPWO2023185778A5 JPWO2023185778A5 (https=) 2026-04-08
JP2025513745A5 JP2025513745A5 (https=) 2026-04-08

Family

ID=88199423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557632A Pending JP2025513745A (ja) 2022-03-28 2023-03-28 新規抗ｆｇｆｒ２抗体

Country Status (9)

Country Link
EP (1) EP4499701A4 (https=)
JP (1) JP2025513745A (https=)
KR (1) KR20250042203A (https=)
CN (1) CN119110806A (https=)
AU (1) AU2023243773A1 (https=)
CA (1) CA3246949A1 (https=)
IL (1) IL315970A (https=)
MX (1) MX2024011805A (https=)
WO (1) WO2023185778A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600596A (zh) * 2024-03-04 2026-01-01 大陸商杭州中美華東製藥有限公司 抗ＦＧＦＲ２ｂ抗體、其抗體藥物偶聯物及其用途
CN118772279B (zh) * 2024-06-28 2025-03-25 北京普利米特生物科技有限公司 抗FGFR2b抗体或其抗原结合片段及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
PH12021552742A1 (en) * 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
KR20220019839A (ko) * 2013-10-08 2022-02-17 다이이찌 산쿄 가부시키가이샤 항 fgfr2 항체와 타제의 조합
EP3287522A4 (en) * 2015-04-20 2019-03-27 Daiichi Sankyo Company, Limited DETECTION OF FGFR2
US20220010020A1 (en) * 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
CA3160810A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
MX2022007961A (es) * 2019-12-24 2022-07-12 Dizal Jiangsu Pharmaceutical Co Ltd Nuevos anticuerpos anti-fgfr2b.
US20230052256A1 (en) * 2019-12-24 2023-02-16 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies

Also Published As

Publication number Publication date
MX2024011805A (es) 2024-11-08
CA3246949A1 (en) 2023-10-05
WO2023185778A1 (en) 2023-10-05
CN119110806A (zh) 2024-12-10
EP4499701A4 (en) 2026-02-25
IL315970A (en) 2024-11-01
WO2023185778A9 (en) 2023-11-02
KR20250042203A (ko) 2025-03-26
EP4499701A1 (en) 2025-02-05
AU2023243773A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
JP7840511B2 (ja) 抗クローディン１８抗体及びそれらの使用の方法
JP2022050522A (ja) 癌の治療のための併用療法
KR102084806B1 (ko) 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도
JP2021510141A (ja) Ｉｇおよびｉｔｉｍドメインを持つｔ細胞免疫受容体（ｔｉｇｉｔ）に対する抗体およびその使用
CN112739718B (zh) 抗tnfrsf9抗体及其用途
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
AU2019382505B2 (en) Anti-PD-1 antibodies and uses thereof
KR20240039006A (ko) 신규 항-sirpa 항체
WO2023185778A9 (en) Novel anti-fgfr2 antibodies
WO2024199362A1 (en) Novel anti-FGFR2 antibodies
JP2024509946A (ja) 抗ヒトｃｘｃｒ５抗体及びその使用
EA052794B1 (ru) Новые антитела против fgfr2
HK40114936A (zh) 新型抗fgfr2抗体
AU2020217012B2 (en) Anti-claudin 18 antibodies and methods of use thereof
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
KR20260026018A (ko) 항-ccr8 항체 및 항-ccr8/ctla4 이중특이성 항체
TW202523694A (zh) 抗muc16抗體及其用途
JP2026508209A (ja) 抗ｉｌ２ｒａ抗体及びその使用
EA048967B1 (ru) Антитела к клаудину 18 и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260326